GLP-1 Medications and Birth Control: What You Need to Know
If you're taking a GLP-1 medication and using oral contraceptives, there's an important interaction to be aware of. Here's a clear breakdown of what the evidence says and what to discuss with your provider.
Key takeaways
GLP-1 medications slow gastric emptying, which may affect how quickly oral birth control is absorbed.
Some providers recommend backup contraception during dose escalation.
Non-oral methods like IUDs, implants, and injections are not affected.
This should be discussed with both your GLP-1 prescriber and your primary care or OB-GYN provider.
The mechanism behind the interaction
Oral contraceptives rely on absorption through the digestive tract. The rate of absorption depends on how quickly the stomach empties into the small intestine.
GLP-1 medications slow gastric emptying, especially during dose escalation. This can delay and potentially reduce peak absorption of oral medications taken around the same time.
In practical terms, this may affect how reliably hormone levels are maintained when using oral birth control.
What the prescribing guidance says
Some GLP-1 prescribing information notes potential effects on oral medication absorption. For oral semaglutide, timing separation is recommended.
For tirzepatide, the Zepbound prescribing information is specific: people who use oral hormonal birth control are advised to switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase.
The semaglutide injection label (Wegovy) does not include that same birth-control instruction, but it does say semaglutide slows stomach emptying and may affect the absorption of oral medicines taken at the same time.
Because of this, many providers recommend a backup method of contraception during the dose escalation phase.
Contraceptive options unaffected by GLP-1 medications
Hormonal IUD
Works locally in the uterus and is not affected by digestion or absorption.
Copper IUD
Non-hormonal and fully localized, with no interaction risk.
Implant
Releases hormones directly into the bloodstream and bypasses the GI tract entirely.
Injection
Administered intramuscularly, so gastric emptying has no effect.
Patch or vaginal ring
Hormone delivery occurs through the skin or vaginal tissue, not the digestive system.
Practical recommendations
If you are using oral birth control and starting GLP-1 therapy, discuss this with your provider before beginning treatment.
Using a backup method during dose escalation is a common precaution. Your provider can guide you based on your specific risk profile and preferences.
Sources
- ZEPBOUND (tirzepatide) Prescribing Information. Eli Lilly and Company.
- WEGOVY (semaglutide) Prescribing Information. Novo Nordisk.
Trial results and prescribing information listed here are for brand-name medications. Compounded semaglutide and tirzepatide are not FDA-approved and were not studied in these trials.
† This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before making changes to your treatment or contraceptive plan.